CD38 and pachyonychia congenita: Combined, these data may help understand the therapeutic targeting achieved by anti-CD38 agents currently used for the treatment of PC malignancies and for highly sensitized patients and autoimmune conditions55,56,57,58 and finally provides an atlas and deep insights into the mechanistic implications of selective depletion of BM ASC subsets.